Search - tctmd.com

Displaying 21 - 40 of 627

Sort: Relevancy | Date

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Todd Neale

September 01, 2025

Presentation ESC 2025

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

Presenter: Duk-Woo Park

August 31, 2025

Presentation ESC 2025

SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease

Presenter: Mårten Falkenberg, Joakim Nordanstig

August 31, 2025

Presentation ESC 2025

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Presenter: Robin Hofmann

August 31, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

Todd Neale

August 31, 2025

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

Presentation ESC 2025

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Presenter: Faiez Zannad

August 30, 2025

Presentation ESC 2025

ABC-AF study: Pragmatic registry-based randomised controlled trial of personalised treatment to reduce stroke or death in atrial fibrillation

Presenter: Jonas Oldgren

August 30, 2025

Presentation ESC 2025

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Presenter: David D. Berg

August 30, 2025

Presentation ESC 2025

BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure

Presenter: Eva Prescott, Dan Atar

August 30, 2025

Presentation ESC 2025

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

August 30, 2025

Presentation ESC 2025

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Presenter: Borja Ibanez

August 30, 2025

Presentation ESC 2025

DANCAVAS 2: Screening and intervention to prevent cardiovascular disease and death

Presenter: Axel Diederichsen

August 30, 2025

Presentation ESC 2025

AQUATIC: Assessment of Quitting versus Using Aspirin Therapy In patients with stabilized Coronary artery disease after stenting who require long-term oral anticoagulation

Presenter: Martine Gilard

August 30, 2025

Presentation ESC 2025

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial

Presenter: Pedro A. Lemos

August 30, 2025

Presentation ESC 2025

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Presenter: Milind Y Desai

August 30, 2025

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Caitlin E. Cox

August 30, 2025

Advertisement

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

ABC-AF study: Pragmatic registry-based randomised controlled trial of personalised treatment to reduce stroke or death in atrial fibrillation

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

DANCAVAS 2: Screening and intervention to prevent cardiovascular disease and death

AQUATIC: Assessment of Quitting versus Using Aspirin Therapy In patients with stabilized Coronary artery disease after stenting who require long-term oral anticoagulation

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content